

Shigeru Chiba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1342842/publications.pdf>

Version: 2024-02-01

188
papers

8,463
citations

117571

34
h-index

49868

87
g-index

213
all docs

213
docs citations

213
times ranked

11312
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cardiac Tamponade as a Recurrence of Angioimmunoblastic T-Cell Lymphoma with the Detection of a p.Gly17Val RHOA Mutation in the Pericardial Effusion. <i>Internal Medicine</i> , 2023, 62, 595-600. | 0.3 | 1 |
| 2 | Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure. <i>Internal Medicine</i> , 2022, , . | 0.3 | 1 |
| 3 | Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples. <i>Cancer Science</i> , 2022, 113, 362-364. | 1.7 | 3 |
| 4 | Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375. | 0.6 | 55 |
| 5 | A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. <i>Nature Cell Biology</i> , 2022, 24, 565-578. | 4.6 | 42 |
| 6 | Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. <i>International Journal of Hematology</i> , 2022, 116, 228-238. | 0.7 | 5 |
| 7 | Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, . | | 259 |
| 8 | Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022, , . | 0.3 | 2 |
| 9 | Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 410-427. | 2.6 | 7 |
| 10 | A simple HPLC assay for determining eltrombopag concentration in human serum. <i>Biomedical Chromatography</i> , 2021, 35, e5049. | 0.8 | 3 |
| 11 | Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 61-70. | 0.3 | 3 |
| 12 | Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. <i>Annals of Hematology</i> , 2021, 100, 1295-1301. | 0.8 | 2 |
| 13 | Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry). <i>Journal of Clinical Medicine</i> , 2021, 10, 1370. | 1.0 | 3 |
| 14 | Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases. <i>British Journal of Haematology</i> , 2021, 195, 585-594. | 1.2 | 5 |
| 15 | Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model. <i>Cancer Science</i> , 2021, 112, 4931-4943. | 1.7 | 21 |
| 16 | EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. <i>Blood</i> , 2021, 138, 610-610. | 0.6 | 2 |
| 17 | Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2021, 138, 1513-1513. | 0.6 | 2 |
| 18 | Germinal Center B Cells Derived from TET2-Mutated Clonal Hematopoiesis Provide a Microenvironmental Niche for Tumor Cells in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 445-445. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | A Single-Cell Atlas of Nonhematopoietic Cells in Human Lymph Node and Lymphoma Reveals Landscape of Stromal Remodeling. <i>Blood</i> , 2021, 138, 447-447. | 0.6 | 0 |
| 20 | S100a8/S100a9-Emmprin-Vegfa Axis Initiated By Tet2-Deficient Immune Cells Exacerbates Lung Cancer Progression through Promotion of Angiogenesis. <i>Blood</i> , 2021, 138, 3276-3276. | 0.6 | 1 |
| 21 | A case of solitary plasmacytoma of bone showing co-expression of both immunoglobulin light chains. <i>European Journal of Medical Research</i> , 2021, 26, 148. | 0.9 | 2 |
| 22 | <i>VAV1</i> mutations contribute to development of T-cell neoplasms in mice. <i>Blood</i> , 2020, 136, 3018-3032. | 0.6 | 15 |
| 23 | Advances in understanding of angioimmunoblastic T-cell lymphoma. <i>Leukemia</i> , 2020, 34, 2592-2606. | 3.3 | 91 |
| 24 | Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556. | 15.2 | 372 |
| 25 | Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. <i>Blood Advances</i> , 2020, 4, 4442-4450. | 2.5 | 29 |
| 26 | Aggressive conjunctival carcinoma arising on poorly controlled sun-damaged graft-versus-host disease. <i>European Journal of Dermatology</i> , 2020, 30, 313-314. | 0.3 | 1 |
| 27 | The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse. <i>International Journal of Hematology</i> , 2020, 112, 200-209. | 0.7 | 6 |
| 28 | Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status. <i>Blood Advances</i> , 2020, 4, 845-854. | 2.5 | 11 |
| 29 | <i>RHOA</i> mutation in follicular T-cell lymphoma: Clinicopathological analysis of 16 cases. <i>Pathology International</i> , 2020, 70, 653-660. | 0.6 | 18 |
| 30 | A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 1726-1735. | 1.3 | 10 |
| 31 | Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma. <i>Cancer Research</i> , 2020, 80, 1875-1884. | 0.4 | 36 |
| 32 | An overlapping case of <i>in situ</i> mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 169-173. | 0.3 | 0 |
| 33 | Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. <i>Blood</i> , 2020, 136, 17-18. | 0.6 | 3 |
| 34 | Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2019, 110, 533-542. | 0.7 | 6 |
| 35 | OX40L-JAG1-Induced Expansion of Lineage-Stable Regulatory T Cells Involves Noncanonical NF- κ B Signaling. <i>Journal of Immunology</i> , 2019, 203, 3225-3236. | 0.4 | 11 |
| 36 | Mutations found in cell-free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. <i>Cancer Science</i> , 2019, 110, 3375-3381. | 1.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. <i>Leukemia</i> , 2019, 33, 2867-2883. | 3.3 | 148 |
| 38 | Notch Signaling in Nestin-Expressing Cells in the Bone Marrow Maintains Erythropoiesis via Macrophage Integrity. <i>Stem Cells</i> , 2019, 37, 924-936. | 1.4 | 2 |
| 39 | “Sleep epileptology” a new field of sleep medicine and epileptology. <i>Sleep and Biological Rhythms</i> , 2019, 17, 1-2. | 0.5 | 1 |
| 40 | Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2019, 2019, 1-5. | 0.3 | 0 |
| 41 | Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. <i>Cancer Science</i> , 2019, 110, 401-407. | 1.7 | 20 |
| 42 | Prominence of nestin-expressing Schwann cells in bone marrow of patients with myelodysplastic syndromes with severe fibrosis. <i>International Journal of Hematology</i> , 2019, 109, 309-318. | 0.7 | 6 |
| 43 | Random Skin Biopsies Before Brain Biopsy for Intravascular Large B-Cell Lymphoma. <i>World Neurosurgery</i> , 2019, 121, e364-e369. | 0.7 | 13 |
| 44 | High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. <i>Annals of Hematology</i> , 2019, 98, 1031-1032. | 0.8 | 15 |
| 45 | The prognosis of disseminated intravascular coagulation associated with hematologic malignancy and its response to recombinant human thrombomodulin. <i>Thrombosis Research</i> , 2019, 173, 57-64. | 0.8 | 3 |
| 46 | Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial. <i>Blood</i> , 2019, 134, 845-845. | 0.6 | 2 |
| 47 | TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 675-675. | 0.6 | 17 |
| 48 | Distinct, Ethnic, Clinical, and Genetic Characteristics of Myelodysplastic Syndromes with Der(1;7). <i>Blood</i> , 2019, 134, 5392-5392. | 0.6 | 2 |
| 49 | Distinct Bone Marrow Microenvironment Abnormalities in MDS and MPN with Fibrosis. <i>Blood</i> , 2019, 134, 2976-2976. | 0.6 | 0 |
| 50 | Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 4216-4216. | 0.6 | 0 |
| 51 | Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. <i>Leukemia Research</i> , 2018, 66, 66-72. | 0.4 | 33 |
| 52 | Liquid biopsy for the identification of intravascular large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, e241-e244. | 1.7 | 53 |
| 53 | Progression to polycythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. <i>Annals of Hematology</i> , 2018, 97, 737-739. | 0.8 | 4 |
| 54 | Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. <i>Cancer Science</i> , 2018, 109, 1682-1689. | 1.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2018, 112, e69-e73. | 0.7 | 26 |
| 56 | Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. <i>Cancer Science</i> , 2018, 109, 225-230. | 1.7 | 57 |
| 57 | Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. <i>International Journal of Hematology</i> , 2018, 108, 447-451. | 0.7 | 7 |
| 58 | Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. <i>International Journal of Hematology</i> , 2018, 107, 211-221. | 0.7 | 10 |
| 59 | Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. <i>Cancer Science</i> , 2018, 109, 490-496. | 1.7 | 37 |
| 60 | An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2018, 1-5. | 0.3 | 8 |
| 61 | Development of automatic classification system for leukocyte images using Random Forest. <i>Electronics and Communications in Japan</i> , 2018, 101, 13-19. | 0.3 | 0 |
| 62 | Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. <i>Leukemia Research</i> , 2018, 74, 137-143. | 0.4 | 7 |
| 63 | Analysis of Genomic Predispositions to Sporadic Myeloid Neoplasms Mediated By DDX41 in Japan. <i>Blood</i> , 2018, 132, 4371-4371. | 0.6 | 0 |
| 64 | Genome-Wide Analysis of Non-Coding Alterations in Pan-Myeloid Cancers Using Whole Genome Sequencing. <i>Blood</i> , 2018, 132, 103-103. | 0.6 | 0 |
| 65 | Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. <i>International Journal of Hematology</i> , 2017, 106, 375-384. | 0.7 | 17 |
| 66 | Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. <i>Nature Communications</i> , 2017, 8, 15068. | 5.8 | 63 |
| 67 | BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. <i>International Journal of Hematology</i> , 2017, 105, 465-469. | 0.7 | 23 |
| 68 | Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling. <i>Scientific Reports</i> , 2017, 7, 39751. | 1.6 | 18 |
| 69 | Dynamics of clonal evolution in myelodysplastic syndromes. <i>Nature Genetics</i> , 2017, 49, 204-212. | 9.4 | 348 |
| 70 | A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). <i>American Journal of Hematology</i> , 2017, 92, 1324-1332. | 2.0 | 9 |
| 71 | Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy. <i>Supportive Care in Cancer</i> , 2017, 25, 2997-3000. | 1.0 | 13 |
| 72 | The Road Map for Megakaryopoietic Lineage from Hematopoietic Stem/Progenitor Cells. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1661-1665. | 1.6 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. <i>Annals of Hematology</i> , 2017, 96, 1641-1652. | 0.8 | 37 |
| 74 | Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1471-1475. | 0.8 | 38 |
| 75 | Dysregulation of TET2 in hematologic malignancies. <i>International Journal of Hematology</i> , 2017, 105, 17-22. | 0.7 | 42 |
| 76 | <i>MYD88</i> (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 2017, 177, 492-494. | 1.2 | 42 |
| 77 | Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 109-119. | 0.3 | 23 |
| 78 | Investigation of new feature vectors to improve an automatic classification accuracy of granulocyte. , 2017, , . | | 0 |
| 79 | Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 54-60. | 0.6 | 7 |
| 80 | A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 41-46. | 0.3 | 10 |
| 81 | NOTCH in Malignant Lymphoma. , 2017, , 79-92. | | 0 |
| 82 | DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. <i>Blood</i> , 2016, 128, 2846-2858. | 0.6 | 43 |
| 83 | Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. <i>Oncology Reports</i> , 2016, 36, 2976-2982. | 1.2 | 14 |
| 84 | Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. <i>International Journal of Hematology</i> , 2016, 104, 548-558. | 0.7 | 27 |
| 85 | Variegated RHOA mutations in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2016, 127, 596-604. | 0.6 | 98 |
| 86 | Clinicopathologic Analysis of Angioimmunoblastic T-cell Lymphoma With or Without RHOA G17V Mutation Using Formalin-fixed Paraffin-embedded Sections. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1041-1050. | 2.1 | 38 |
| 87 | Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. <i>International Journal of Hematology</i> , 2016, 103, 53-62. | 0.7 | 21 |
| 88 | A nationwide survey of co-occurrence of malignant lymphomas and myelodysplastic syndromes/myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2016, 95, 829-830. | 0.8 | 4 |
| 89 | Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study. <i>Blood</i> , 2016, 128, 1916-1916. | 0.6 | 6 |
| 90 | NGS-Based Copy Number Analysis in 1,185 Patients with Myeloid Neoplasms. <i>Blood</i> , 2016, 128, 955-955. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Notch Signaling in Bone Marrow Nestin-Expressing Cells Controls Balance of Erythropoiesis at the Bone Marrow and Spleen. <i>Blood</i> , 2016, 128, 432-432. | 0.6 | 0 |
| 92 | Genetic Landscape and Clonal Evolution Following 5-Aza Therapy in Patients with High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4304-4304. | 0.6 | 0 |
| 93 | Integrated Molecular Analysis of Myelodysplastic Syndromes Using Whole Genome Sequencing. <i>Blood</i> , 2016, 128, 5512-5512. | 0.6 | 0 |
| 94 | Foxp3+ regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells. <i>Blood</i> , 2016, 128, 431-431. | 0.6 | 0 |
| 95 | Analysis of the Prevalence and Risk Factors of Adult Neutropenia in a Large Cohort in Japan. <i>Blood</i> , 2016, 128, 4738-4738. | 0.6 | 0 |
| 96 | Targeting Complete Response with Upfront Bortezomib Followed By Autologous Transplantation and Consolidation Therapy for Untreated Multiple Myeloma (TUBA study). <i>Blood</i> , 2016, 128, 3463-3463. | 0.6 | 0 |
| 97 | Abnormal Increase in a Distinct Subset of Nestin-Expressing Cells in the Bone Marrow of Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 3887-3887. | 0.6 | 1 |
| 98 | Association of Increased Ring Ssideroblasts with Inferior Survival in Patients with Myelodysplastic Syndrome with Multi-Lineage Dysplasia. <i>Blood</i> , 2016, 128, 5530-5530. | 0.6 | 0 |
| 99 | Recurrent VAV1 Abnormalities in Angioimmunoblastic T Cell Lymphoma. <i>Blood</i> , 2016, 128, 4104-4104. | 0.6 | 1 |
| 100 | the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4287-4287. | 0.6 | 0 |
| 101 | Whole-Genome Sequencing of Primary Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4112-4112. | 0.6 | 2 |
| 102 | Genome-wide surveillance of mismatched alleles for graft-versus-host disease in stem cell transplantation. <i>Blood</i> , 2015, 126, 2752-2763. | 0.6 | 31 |
| 103 | Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the Dâ€™first study. <i>American Journal of Hematology</i> , 2015, 90, 819-824. | 2.0 | 32 |
| 104 | Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4. | 0.3 | 1 |
| 105 | Age-Dependent Decrease of DNA Hydroxymethylation in Human T Cells. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2015, 55, 1-6. | 0.3 | 25 |
| 106 | Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes. <i>Stem Cells</i> , 2015, 33, 2196-2207. | 1.4 | 50 |
| 107 | Double somatic mosaic mutations in TET2 and DNMT3Aâ€™’origin of peripheral T cell lymphoma in a case. <i>Annals of Hematology</i> , 2015, 94, 1221-1223. | 0.8 | 20 |
| 108 | G17V RHOA: Genetic evidence of GTP-unbound RHOA playing a role in tumorigenesis in T cells. <i>Small GTPases</i> , 2015, 6, 100-103. | 0.7 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Guest editorial: pre-leukemia/pre-lymphoma“ what is old, what is new?. International Journal of Hematology, 2015, 102, 511-512. | 0.7 | 1 |
| 110 | Molecular Pathogenesis of Peripheral T Cell Lymphoma. Current Hematologic Malignancy Reports, 2015, 10, 429-437. | 1.2 | 13 |
| 111 | Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab. Annals of Hematology, 2015, 94, 2061-2062. | 0.8 | 2 |
| 112 | Detection of the G17V RHOA Mutation in Angioimmunoblastic T-Cell Lymphoma and Related Lymphomas Using Quantitative Allele-Specific PCR. PLoS ONE, 2014, 9, e109714. | 1.1 | 24 |
| 113 | Disease-specific mutations in mature lymphoid neoplasms: Recent advances. Cancer Science, 2014, 105, 623-629. | 1.7 | 14 |
| 114 | Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome. SpringerPlus, 2014, 3, 501. | 1.2 | 11 |
| 115 | Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood following a Second Relapse. Case Reports in Hematology, 2014, 2014, 1-3. | 0.3 | 2 |
| 116 | Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genetics, 2014, 46, 171-175. | 9.4 | 542 |
| 117 | Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen. Oncology Research and Treatment, 2014, 37, 378-383. | 0.8 | 10 |
| 118 | In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations. Blood, 2014, 124, 823-823. | 0.6 | 4 |
| 119 | Novel Biological Effects and Distinct Patterns of Rhoa Mutations in Adult T-Cell Leukemia/Lymphoma and Angioimmunoblastic T Cell Lymphoma. Blood, 2014, 124, 2215-2215. | 0.6 | 0 |
| 120 | Baseline Assessment Of GPI-Anchored Protein Deficient Blood Cells In Patients With Bone Marrow Failure (The OPTIMA study). Blood, 2013, 122, 1241-1241. | 0.6 | 1 |
| 121 | Hypermethylation of Bcl6 Is a Potential Cause of Development of Lymphoma with Tfh Features in Tet2 Knockdown Mice. Blood, 2013, 122, 2490-2490. | 0.6 | 1 |
| 122 | Peripherally Inserted Central Catheters Are a Good Option For Venous Access In The Patients With Hematologic Diseases. Blood, 2013, 122, 2956-2956. | 0.6 | 2 |
| 123 | Clinical “MUTATOME” Of Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leukemia. Blood, 2013, 122, 518-518. | 0.6 | 2 |
| 124 | Somatic G17V Rhoa Mutation Specifies Angioimmunoblastic T-Cell Lymphoma. Blood, 2013, 122, 815-815. | 0.6 | 2 |
| 125 | Hes1 Is Responsible For Notch Signaling-Mediated Suppression Of Acute Myeloid Leukemia Development Via Suppression Of FLT3 Expression. Blood, 2013, 122, 3800-3800. | 0.6 | 0 |
| 126 | Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 5454-5454. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | A Novel Diagnostic Method For AITL By Detecting RHOA G17V Hotspot Mutation Using Allele-Specific Real-Time PCR. <i>Blood</i> , 2013, 122, 3000-3000. | 0.6 | 0 |
| 128 | Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant Therapy Without Causing Severe Hemorrhagic Events. <i>Blood</i> , 2013, 122, 2381-2381. | 0.6 | 0 |
| 129 | Notch2 and Immune Function. <i>Current Topics in Microbiology and Immunology</i> , 2012, 360, 151-161. | 0.7 | 12 |
| 130 | Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. <i>International Journal of Hematology</i> , 2012, 96, 492-500. | 0.7 | 19 |
| 131 | Nine years interval between first and second bone marrow transplantations and subsequent long-term survival—a case of acute myeloid leukemia with MLL-AF6 fusion gene. <i>Annals of Hematology</i> , 2012, 91, 1491-1493. | 0.8 | 1 |
| 132 | First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) — A Systematic Review and Individual Patient Data Meta-Analysis. <i>Blood</i> , 2012, 120, 3655-3655. | 0.6 | 1 |
| 133 | Transcription Factor Hes1 Functions As a Tumor Suppressor in MLL-Associated Acute Leukemia. <i>Blood</i> , 2012, 120, 118-118. | 0.6 | 0 |
| 134 | Recurrent Mutations of Multiple Components of Cohesin Complex in Myeloid Neoplasms. <i>Blood</i> , 2012, 120, 782-782. | 0.6 | 1 |
| 135 | Implication of the Distinct Differentiation Pathway of Megakaryocytes From Hematopoietic Stem Cells in the Mouse Bone Marrow. <i>Blood</i> , 2012, 120, 1204-1204. | 0.6 | 0 |
| 136 | Soluble Recombinant Thrombomodulin Is a Potentially Promising Agent without Causing Severe Hemorrhagic Events for Hematological Malignancy-Induced Disseminated Intravascular Coagulation. <i>Blood</i> , 2012, 120, 3413-3413. | 0.6 | 0 |
| 137 | c-Maf plays a crucial role for the definitive erythropoiesis that accompanies erythroblastic island formation in the fetal liver. <i>Blood</i> , 2011, 118, 1374-1385. | 0.6 | 49 |
| 138 | Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2011, 93, 618-623. | 0.7 | 23 |
| 139 | Mutational Spectrum Analysis of Interesting Correlation and Interrelationship Between RNA Splicing Pathway and Commonly Targeted Genes in Myelodysplastic Syndrome. <i>Blood</i> , 2011, 118, 273-273. | 0.6 | 2 |
| 140 | Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia. <i>Blood</i> , 2011, 118, 458-458. | 0.6 | 8 |
| 141 | Detection of CD55- and CD59-Negative Immature Reticulocytes May Improves Sensitivity/Specificity to Identify a Minor Population of PNH-Type Cells in Patients with Myelodysplastic Syndrome/Aplastic Anemia. <i>Blood</i> , 2011, 118, 4373-4373. | 0.6 | 0 |
| 142 | Functional Analysis of SRSF2 Mutations in Myelodysplastic Syndromes and Related Disorders. <i>Blood</i> , 2011, 118, 1706-1706. | 0.6 | 0 |
| 143 | Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. <i>Blood</i> , 2010, 115, 2872-2881. | 0.6 | 67 |
| 144 | Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum. <i>International Journal of Hematology</i> , 2010, 92, 474-480. | 0.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 617-623. | 0.7 | 19 |
| 146 | Whole Exome Analysis of Myelodysplastic Syndromes Using Next-Generation Resequencing Technology. <i>Blood</i> , 2010, 116, 295-295. | 0.6 | 0 |
| 147 | Profiling of Multiple Gene Mutations In Myelodysplastic Syndromes Using High-Throughput Resequencing Combined with Barcode Labeling. <i>Blood</i> , 2010, 116, 4011-4011. | 0.6 | 0 |
| 148 | Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2009, 100, 920-926. | 1.7 | 144 |
| 149 | Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. <i>Cancer Science</i> , 2009, 100, 2444-2450. | 1.7 | 27 |
| 150 | Frequent inactivation of A20 in B-cell lymphomas. <i>Nature</i> , 2009, 459, 712-716. | 13.7 | 520 |
| 151 | Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. <i>Nature</i> , 2009, 460, 904-908. | 13.7 | 380 |
| 152 | Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 70-78. | 1.5 | 72 |
| 153 | Genome-Wide Analysis of MDS/MPD Disclosed Frequent Homozygous C-Cbl mutations Tightly Associated with 11q-UPD. <i>Blood</i> , 2008, 112, 855-855. | 0.6 | 2 |
| 154 | Genome-Wide Association Studies of Genetic Incompatibility That Is Relevant to the Development of GvHD in Unrelated Bone Marrow Transplantation. <i>Blood</i> , 2008, 112, 715-715. | 0.6 | 1 |
| 155 | Exploring Genetic Basis of GVHD by Whole-Genome Association Studies in a Large Series from the Japan Marrow Donation Program (JMDP).. <i>Blood</i> , 2007, 110, 3232-3232. | 0.6 | 0 |
| 156 | Implication of AML1/RUNX1 Function in the Homeostasis and Leukemic Transformation of Hematopoietic Stem Cells.. <i>Blood</i> , 2007, 110, 4117-4117. | 0.6 | 0 |
| 157 | Highly Efficient Ex Vivo Expansion of Human Hematopoietic Stem Cells Using Delta1-Fc Chimeric Protein. <i>Stem Cells</i> , 2006, 24, 2456-2465. | 1.4 | 79 |
| 158 | Concise Review: Notch Signaling in Stem Cell Systems. <i>Stem Cells</i> , 2006, 24, 2437-2447. | 1.4 | 370 |
| 159 | Notch Signaling in Hematopoietic Stem Cells. <i>International Journal of Hematology</i> , 2005, 82, 285-294. | 0.7 | 46 |
| 160 | Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300. <i>Cancer Science</i> , 2005, 96, 274-282. | 1.7 | 65 |
| 161 | A Robust Algorithm for Copy Number Detection Using High-Density Oligonucleotide Single Nucleotide Polymorphism Genotyping Arrays. <i>Cancer Research</i> , 2005, 65, 6071-6079. | 0.4 | 593 |
| 162 | Genome-Wide Analysis of Copy Number Alterations/LOH/Allelic Imbalances in Non-Hodgkin Lymphoma Using Ultrahigh-Density SNP-Genotyping Microarrays with the Robust CNAG Algorithms.. <i>Blood</i> , 2005, 106, 420-420. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Genome-Wide Analysis of Copy Number Analysis of Myelodysplastic Syndromes Using High-Density SNP-Genotyping Microarrays.. Blood, 2005, 106, 3420-3420. | 0.6 | 0 |
| 164 | Ki23819 (KRN383â€œHCl) Inhibits Kinase Activity of Wild Type and Mutant FLT3 Receptor Tyrosine Kinase In Vitro.. Blood, 2004, 104, 1168-1168. | 0.6 | 0 |
| 165 | Frequent but Reversible and Manageable Cardiac Complications after Successful Haploidentical HLA-Mismatched Hematopoietic Stem Cell Transplantation (HSCT) without Ex Vivo Graft Manipulation.. Blood, 2004, 104, 1841-1841. | 0.6 | 7 |
| 166 | Notch2 Is Preferentially Expressed in Mature B Cells and Indispensable for Marginal Zone B Lineage Development. Immunity, 2003, 18, 675-685. | 6.6 | 499 |
| 167 | Notch1 but Not Notch2 Is Essential for Generating Hematopoietic Stem Cells from Endothelial Cells. Immunity, 2003, 18, 699-711. | 6.6 | 416 |
| 168 | Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. American Journal of Hematology, 2001, 66, 85-91. | 2.0 | 16 |
| 169 | Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. British Journal of Haematology, 2000, 109, 435-437. | 1.2 | 15 |
| 170 | Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Therapy, 2000, 7, 144-150. | 2.2 | 12 |
| 171 | Binding of Delta1, Jagged1, and Jagged2 to Notch2 Rapidly Induces Cleavage, Nuclear Translocation, and Hyperphosphorylation of Notch2. Molecular and Cellular Biology, 2000, 20, 6913-6922. | 1.1 | 155 |
| 172 | Mouse Jagged1 Physically Interacts with Notch2 and Other Notch Receptors. Journal of Biological Chemistry, 1999, 274, 32961-32969. | 1.6 | 212 |
| 173 | Serial serum thrombopoietin levels in a pregnant woman with essential thrombocythaemia.. British Journal of Haematology, 1999, 105, 271-273. | 1.2 | 4 |
| 174 | Increased Serum Soluble Fas Ligand Associated with Recurrent B-Cell Non-Hodgkin's Lymphoma after Autologous Peripheral Blood Stem Cell Transplantation. Leukemia and Lymphoma, 1999, 34, 625-628. | 0.6 | 11 |
| 175 | Long-Term Third Chronic Phase of Chronic Myelogenous Leukemia Maintained by Interferon-Î± and Methotrexate. Leukemia and Lymphoma, 1999, 33, 193-197. | 0.6 | 2 |
| 176 | The oncoprotein Evi-1 represses TGF-Î² signalling by inhibiting Smad3. Nature, 1998, 394, 92-96. | 13.7 | 338 |
| 177 | Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. , 1998, 16, 33-37. | | 38 |
| 178 | QUANTITATION OF HEPATITIS G VIRUS RNA IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS. British Journal of Haematology, 1998, 100, 798-799. | 1.2 | 4 |
| 179 | Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematological Oncology, 1998, 16, 33-37. | 0.8 | 1 |
| 180 | Circulating late-stage erythroid progenitors in a patient with agnagenic myeloid metaplasia. American Journal of Hematology, 1994, 45, 194-195. | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Effect of stem cell factor (c-kit ligand) on clonogenic leukemic precursor cells: Synergy with other hematopoietic growth factors. <i>American Journal of Hematology</i> , 1994, 47, 328-330. | 2.0 | 7 |
| 182 | Marked and reproducible increase in trilineage blood cell counts by administration of granulocyte colony-stimulating factor in a patient with refractory anaemia with excess blasts in transformation. <i>British Journal of Haematology</i> , 1994, 86, 665-667. | 1.2 | 6 |
| 183 | Structural and functional analyses of glycosylation on the distinct molecules of human GM-CSF receptors. <i>FEBS Journal</i> , 1991, 198, 659-666. | 0.2 | 17 |
| 184 | IL-3 specifically inhibits GM-CSF binding to the higher affinity receptor. <i>Journal of Cellular Physiology</i> , 1991, 146, 251-257. | 2.0 | 35 |
| 185 | Frequent expression of receptors for granulocyte-macrophage colony-stimulating factor on human nonhematopoietic tumor cell lines. <i>Journal of Cellular Physiology</i> , 1990, 143, 483-487. | 2.0 | 43 |
| 186 | Treatment of childhood-onset cyclic neutropenia with recombinant human granulocyte colony-stimulating factor. <i>European Journal of Haematology</i> , 1990, 45, 110-111. | 1.1 | 8 |
| 187 | Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. <i>Journal of Cellular Physiology</i> , 1989, 140, 323-334. | 2.0 | 786 |
| 188 | Binding Properties and Proliferative Effects of Human Recombinant Granulocyte-Macrophage Colony-stimulating Factor in Primary Leukemia and Lymphoma. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 887-894. | 1.7 | 2 |